Visaka Industries Limited (NSE:VISAKAIND)
India · Delayed Price · Currency is INR 85.89
+1.67 (1.98%)
Aug 1, 2025, 3:28 PM IST
Ligand Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 15,433 | 15,266 | 16,534 | 14,158 | 11,465 | Upgrade |
| 15,433 | 15,266 | 16,534 | 14,158 | 11,465 | Upgrade | |
Revenue Growth (YoY) | 1.09% | -7.67% | 16.78% | 23.49% | 9.15% | Upgrade |
Cost of Revenue | 8,607 | 8,406 | 9,022 | 6,841 | 5,323 | Upgrade |
Gross Profit | 6,826 | 6,860 | 7,512 | 7,317 | 6,142 | Upgrade |
Selling, General & Admin | 1,721 | 1,721 | 1,752 | 1,617 | 1,510 | Upgrade |
Other Operating Expenses | 4,133 | 4,259 | 4,375 | 3,703 | 2,697 | Upgrade |
Operating Expenses | 6,501 | 6,571 | 6,633 | 5,701 | 4,612 | Upgrade |
Operating Income | 325.6 | 288.38 | 879.4 | 1,616 | 1,531 | Upgrade |
Interest Expense | -435.55 | -364.55 | -216.03 | -106.27 | -123.73 | Upgrade |
Interest & Investment Income | 30.39 | 56.03 | 57.98 | 30.71 | 31.77 | Upgrade |
Currency Exchange Gain (Loss) | 18.04 | 0.97 | 26.21 | 7.35 | 5.2 | Upgrade |
Other Non Operating Income (Expenses) | 35.48 | 45.24 | 35.35 | 51.62 | 41.41 | Upgrade |
EBT Excluding Unusual Items | -26.06 | 26.08 | 782.9 | 1,600 | 1,485 | Upgrade |
Merger & Restructuring Charges | - | - | -32.06 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.17 | -18.88 | 3.18 | 1.27 | Upgrade |
Asset Writedown | -0.41 | -0.87 | -1.02 | -0.86 | -1.01 | Upgrade |
Pretax Income | -19.98 | 29.93 | 735.74 | 1,606 | 1,493 | Upgrade |
Income Tax Expense | 10.14 | 21.34 | 199.87 | 422.66 | 386.13 | Upgrade |
Net Income | -30.12 | 8.6 | 535.87 | 1,183 | 1,106 | Upgrade |
Net Income to Common | -30.12 | 8.6 | 535.87 | 1,183 | 1,106 | Upgrade |
Net Income Growth | - | -98.40% | -54.71% | 6.94% | 124.45% | Upgrade |
Shares Outstanding (Basic) | 86 | 86 | 86 | 83 | 81 | Upgrade |
Shares Outstanding (Diluted) | 86 | 86 | 86 | 85 | 82 | Upgrade |
Shares Change (YoY) | - | - | 1.39% | 4.19% | 3.01% | Upgrade |
EPS (Basic) | -0.35 | 0.10 | 6.20 | 14.23 | 13.69 | Upgrade |
EPS (Diluted) | -0.35 | 0.10 | 6.20 | 13.88 | 13.53 | Upgrade |
EPS Growth | - | -98.40% | -55.33% | 2.62% | 117.88% | Upgrade |
Free Cash Flow | 838.52 | -1,158 | -1,990 | -921.69 | 2,400 | Upgrade |
Free Cash Flow Per Share | 9.70 | -13.40 | -23.03 | -10.81 | 29.34 | Upgrade |
Dividend Per Share | 0.500 | 0.500 | 2.000 | 3.000 | 3.000 | Upgrade |
Dividend Growth | - | -75.00% | -33.33% | - | - | Upgrade |
Gross Margin | 44.23% | 44.94% | 45.43% | 51.68% | 53.57% | Upgrade |
Operating Margin | 2.11% | 1.89% | 5.32% | 11.42% | 13.35% | Upgrade |
Profit Margin | -0.19% | 0.06% | 3.24% | 8.36% | 9.65% | Upgrade |
Free Cash Flow Margin | 5.43% | -7.58% | -12.03% | -6.51% | 20.93% | Upgrade |
EBITDA | 963.21 | 869.77 | 1,381 | 1,993 | 1,931 | Upgrade |
EBITDA Margin | 6.24% | 5.70% | 8.35% | 14.07% | 16.84% | Upgrade |
D&A For EBITDA | 637.61 | 581.39 | 501.89 | 376.18 | 399.9 | Upgrade |
EBIT | 325.6 | 288.38 | 879.4 | 1,616 | 1,531 | Upgrade |
EBIT Margin | 2.11% | 1.89% | 5.32% | 11.42% | 13.35% | Upgrade |
Effective Tax Rate | - | 71.28% | 27.17% | 26.32% | 25.87% | Upgrade |
Revenue as Reported | 15,514 | 15,373 | 16,640 | 14,257 | 11,551 | Upgrade |
Advertising Expenses | 288.2 | 323.31 | 326.03 | 247.66 | 270.86 | Upgrade |
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.